Takeda Pharmaceutical Company Limited (TAK)
- Previous Close
13.07 - Open
13.08 - Bid 13.00 x 4000
- Ask 13.20 x 3000
- Day's Range
13.01 - 13.08 - 52 Week Range
13.01 - 17.11 - Volume
1,212,673 - Avg. Volume
1,835,537 - Market Cap (intraday)
41.198B - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
36.19 - EPS (TTM)
0.36 - Earnings Date --
- Forward Dividend & Yield 0.64 (4.88%)
- Ex-Dividend Date Sep 28, 2023
- 1y Target Est
18.24
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
www.takeda.com49,095
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: TAK
Performance Overview: TAK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TAK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TAK
Valuation Measures
Market Cap
41.32B
Enterprise Value
69.32B
Trailing P/E
35.97
Forward P/E
22.78
PEG Ratio (5yr expected)
3.20
Price/Sales (ttm)
1.53
Price/Book (mrq)
0.94
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
4.28%
Return on Assets (ttm)
2.61%
Return on Equity (ttm)
2.76%
Revenue (ttm)
4.17T
Net Income Avi to Common (ttm)
178.22B
Diluted EPS (ttm)
0.36
Balance Sheet and Cash Flow
Total Cash (mrq)
288.36B
Total Debt/Equity (mrq)
77.21%
Levered Free Cash Flow (ttm)
-9.88B